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Background: Herein, the signiﬁcance of post-transplant glomerulonephritis (PTGN)
has been revisited to investigate whether PTGN induces allograft failure. The aim of
this study was to identify the incidence of PTGN and its association with allograft
failure, as well as to analyze the risk factors for PTGN.
Methods: Among the 996 Korean patients who underwent kidney transplantation
in a multicenter cohort from 1995 to 2010, 764 patients were enrolled in this study.
Results: The incidence rate of PTGN was 9.7% and 17.0% at 5 and 10 years of follow-
up, respectively. PTGN was diagnosed in 17.8% of the recipients with results of
biopsy tests or clinical diagnosis identifying glomerular diseases as the underlying
cause, compared with 0.0%, 4.4%, 4.9%, 5.5%, and 5.7% of the recipients with renal
vascular diseases, renal interstitial diseases/pyelonephritis/uropathy, diabetic renal
disease, hereditary renal diseases, and diseases with unknown etiologies, respec-
tively. Allograft survival was signiﬁcantly decreased in patients with PTGN. PTGN
was associated with a fourfold increase in graft failure with a hazard ratio of 7.11 for
both acute rejection and PTGN. Results of the risk factor analysis for PTGN revealed
that the underlying glomerular renal diseases and treatment methods using drugs
such as tacrolimus and basiliximab signiﬁcantly increased PTGN development, after
adjusting for other risk factors.
Conclusion: We conclude that PTGN is strongly associated with poor kidney
allograft survival. Therefore, optimal management of recurrent or de novo GN should
be the critical focus of post-transplant care.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).rean Society of Nephrology. P
ses/by-nc-nd/4.0/).
Medicine, Seoul National
bang 2-dong, Dongjak-gu,Introduction
Chronic glomerulonephritis (GN) is one of the main etiologies
of end-stage renal disease (ESRD), and is an indication for kidney
transplantation in 30–50% of the recipients with renal dis-
eases [1]. Although much improvement in immunosuppressive
regimens for the treatment of renal diseases has been achievedublished by Elsevier. This is an open access article under the CC BY-NC-
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signiﬁcantly improved [2–4].
Along with the major impact of interstitial ﬁbrosis, tubular
atrophy, and chronic rejection on allograft outcome, recurrence or
de novo development of GN (post-transplant glomerulonephritis
or PTGN) may be one of the factors affecting long-term out-
come [5,6].
GN of all types may recur or develop soon after kidney
transplantation and the prevalence of PTGN depends on the
original underlying kidney disease. For example, the prevalence
rate is 20–50% in membranoproliferative GN (MPGN) Type I,
80–100% in MPGN Type II, 20–50% in focal segmental glomer-
ulosclerosis (FSGS), 13–50% in immunoglobulin A nephropathy
(IgAN), and 10–30% in membranous nephropathy (MN) [7].
Our recent work highlights the signiﬁcant effect of IgAN
recurrence on allograft outcome, the results of which revealed
that chronic changes negatively affected allograft outcome
more signiﬁcantly than IgAN recurrence [8]. Although the
data are limited, the development of various types of PTGN
and kidney allograft failure due to PTGN has been reported
in patients with underlying chronic GN [9–11]. By contrast,
many patients with chronic kidney disease with unknown
etiology progress to ESRD and had to undergo renal trans-
plantation; however, allograft outcome in these groups of
patients has not been thoroughly investigated.
Therefore, we aimed to investigate and identify the inci-
dence, risk factors, and the effect of PTGN on graft survival in
both patients with chronic GN and patients with ESRD of
unknown etiology.Methods
Study population
We enrolled 764 of the 996 patients who underwent
kidney transplantation at Seoul National University Hospital,
Seoul National University Bundang Hospital, and Seoul
National University Boramae Medical Center between 1995
and 2010. We excluded patients who were under 18 years of
age and those who were retransplanted or underwent multi-
organ transplantation. This study was approved by the Seoul
National University Hospital Institutional Review Board. All
clinical investigations were conducted in accordance with the
guidelines set by the 2008 Declaration of Helsinki.
Data collection
Patient gender, age, comorbidities, donor type, human
leukocyte antigen (HLA) status, original kidney disease, date
of referral, date of transplantation, and regimens of immuno-
suppressant drugs were recorded. Original kidney diseases
were classiﬁed into six groups as follows: glomerular diseases,
renal vascular diseases, renal interstitial diseases/pyelone-
phritis (PN)/uropathy, diabetic renal disease, hereditary renal
diseases, and diseases with unknown etiologies. These diseases
were diagnosed based on the results of kidney biopsy tests or
imaging studies such as computed tomography, magnetic
resonance imaging, and kidney ultrasonography, or based on
clinical judgments by physicians and researchers. Early referral
was deﬁned as the interval between the nephrologist’s visit
and the diagnosis of ESRD or the start date of renal replace-
ment therapy greater than 1 year.Hypertension was deﬁned as a systolic blood pressure greater
than or equal to 140 mmHg, diastolic pressure greater than or
equal to 90 mmHg, or the concurrent use of antihypertensive
medications. Diabetes mellitus was diagnosed in patients with
random blood glucose concentration levels greater than or equal
to 200 mg/dL, fasting plasma glucose levels greater than or equal
to 126 mg/dL on at least two separate occasions, or in patients
using antihyperglycemic drugs.
Clinical parameters such as serum creatinine, estimated glo-
merular ﬁltration rate (eGFR), hematuria, and daily proteinuria
that could have inﬂuenced the development of PTGN while
performing biopsy of the kidney were collected. Serum creatinine
levels were measured using an assay based on Jaffe’s method
and eGFR was calculated using Modiﬁcation of Diet in Renal
Disease formula (MDRD): GFR (mL/minute/1.73 m2)¼186
(Scr)
1.154 (age in years)0.203 (0.742 if female).
PTGN and graft outcome
Biopsies of the allograft were performed when eGFR fell
below 60 mL/minute or clinically signiﬁcant hematuria (gross
hematuria or red blood cell count Z5/high power ﬁeld in
urinalysis and microscopy) or proteinuria [random urine
protein-to-creatinine ratio (PCR) 40.5] developed. All protocol
biopsies were excluded from the study. Acute rejection or PTGN
was diagnosed by accurate histological classiﬁcation based on
the results of kidney biopsy. However, biopsy-unproven cases
but with clinical indications that are mentioned above were not
classiﬁed as PTGN. The date of diagnosis of PTGN was recorded
as the date of biopsy. Graft failure was deﬁned as the require-
ment for permanent dialysis or allograft nephrectomy, retrans-
plantation, and censoring the recipient’s death.
Immunosuppressive treatment protocols
A standardized immunosuppression protocol involving a
combination of a calcineurin inhibitor and steroids was initiated
within 24 hours of surgery. The choice of calcineurin inhibitor,
either cyclosporine A (CsA) or tacrolimus, was determined by
the transplantation team. The initial dose of CsA was 10 mg/kg
per day by the oral route; target trough levels were 200–400 ng/
mL during the ﬁrst 4 weeks and 100–200 ng/mL thereafter. The
initial dose of tacrolimus was 0.16 mg/kg per day by the oral
route; target trough levels were 8–15 ng/mL during the ﬁrst
3 months and 3–8 ng/mL thereafter. Methylprednisolone (1 g/
day) was administered by intravenous infusion on the day of
transplantation, tapered to prednisone at 30 mg/day on post-
transplantation day four, and then administered at the main-
tenance dose without withdrawal. Inhibitors of purine synthesis
[e.g., mycophenolate mofetil (MMF)] were used in the initial
immunosuppressive treatment based on clinical judgments
considering risk factors such as HLA mismatch.
Statistical analysis
We compared the categorical variables using the Chi-square
test and continuous variables expressed as the mean7
standard deviation were compared using the Student t test or
one-way analysis of variance. The Kaplan–Meier method was
used to estimate the incidence rate of PTGN and graft failure as
well as to compare cumulative probability of PTGN with several
risk factors (log-rank test). The effect of PTGN on death-censored
graft failure was also evaluated using Kaplan–Meier analysis.
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association between multiple risk factors and PTGN occurrence.
While performing multivariate analysis, statistically signiﬁcant
covariates from the univariate analysis (Po0.01) were selected.
A P value o0.05 was considered to be statistically signiﬁcant.
Statistical analysis was performed using SPSS version 18.0
software (SPSS Inc., Chicago, IL, USA).
Results
Patient demographics
Patient demographics are shown in Table 1. Mean duration
of follow-up was 60.71750.77 (range: 0.4–182.5) months. As
underlying renal diseases, among overall 764 recipients, 292
(38.2%) had glomerular diseases, and 131 (17.1%), 45 (5.9%), 82
(10.7%), and 73 (9.6%) were classiﬁed to as having renal
vascular diseases, renal interstitial diseases/PN/uropathy, dia-
betic renal disease, and hereditary renal diseases, respectively.
The remaining 141 (18.5%) patients underwent kidney trans-
plantation due to renal failure caused by unknown etiologies.
Of the 292 patients in the glomerular diseases group, histolo-
gical conﬁrmation was performed in 195 (66.8%) patients. The
results of which are as follows: 66.1% of the patients are with
IgAN, 8.2% with FSGS, 7.2% with lupus nephritis, 4.1% with
MPGN, 2.1% with MN, and 12.3% with other GN (Table 2).Table 1. Baseline characteristics classiﬁed by underlying kidney diseas
Total
(N¼764)
Glomerular
(N¼292, 38.2%)
Vascular
(N¼131, 17.1%)
Era
1995–2000 173 (22.6) 72 (24.7) 33 (25.2)
2001–2005 235 (30.8) 89 (30.5) 45 (34.4)
2006–2010 356 (46.6) 131 (44.8) 53 (40.4)
HLA mismatch
Unknown 22 (2.9) 8 (2.7) 0 (0)
0 100 (13.1) 44 (15.1) 13 (9.9)
1–3 410 (53.7) 162 (55.5) 77 (58.8)
4–6 232 (30.3) 78 (26.7) 41 (31.3)
Male (recipient) 446 (58.4) 167 (57.2) 83 (63.4)
Male (donor) 406 (54.0) 161 (56.1) 77 (58.8)
Donor type
Living related 451 (59.0) 190 (65.1) 75 (57.3)
Living unrelated 141 (18.5) 42 (14.4) 35 (26.7)
Deceased 172 (22.5) 60 (20.5) 21 (16.0)
Referral
Early (Z1 y) 569 (74.5) 249 (85.3) 71 (54.2)
Late (o1 y) 178 (23.3) 38 (13.0) 54 (41.2)
Unknown 17 (2.2) 5 (1.7) 6 (4.6)
Pre-emptive 274 (35.9) 113 (38.7) 50 (38.2)
Diabetes mellitus 93 (12.2) 3 (1.0) 2 (1.5)
Hypertension 523 (68.5) 192 (65.8) 131 (100.0)
Immunosuppressants
Calcineurin inhibitors
Cyclosporine A 369 (48.3) 137 (46.9) 71 (54.2)
Tacrolimus 389 (50.9) 155 (53.1) 58 (44.3)
Others 6 (0.8) 0 (0) 2 (1.5)
Purine synthesis inhibitors
Not use 82 (10.7) 35 (12.0) 17 (13.0)
MMF 574 (75.2) 215 (73.6) 90 (68.7)
Azathioprine 107 (14.0) 41 (14.0) 24 (18.3)
Others 1 (0.1) 1 (0.4) 0 (0)
Basiliximab 322 (42.1) 115 (39.4) 50 (38.2)
Age at transplantn 41.49711.97 38.69711.06 46.18710.60
Donor agen 38.80712.26 38.25711.71 38.58710.95
n Data expressed as mean7standard deviation (in years).
HLA, human leukocyte antigen; MMF, mycophenolate mofetil; PN, pyeloneRegarding donor type, living related donors were the most
common, followed by deceased and living unrelated donors. A
total of 569 (74.5%) patients were referred early to nephrol-
ogists. A total of 274 patients (35.9%) received pre-emptive
transplantation. Tacrolimus and CsA were administered to
50.9% and 48.3% of recipients, while 42.1% received basilix-
imab pretransplantation. MMF was the most commonly used
antimetabolite antirejection drug (75.1%).
Incidence of PTGN and its impact on graft survival
During follow-up, 70 (9.2%) patients were diagnosed
with PTGN. At diagnosis, serum creatinine level was 1.887
2.24 mg/dL, eGFR was 49.67720.97 mL/minute, and random
urine PCR was 2.5773.18 g (Supplementary Table 1).
The incidence of PTGN increased with time after trans-
plantation, from 4.9% at 2 years to 9.7% at 5 years, and 17.0%
at 10 years of follow-up. PTGN occurred steadily throughout
the follow-up period, while most acute rejection episodes
developed early (Fig. 1).
Regarding underlying kidney diseases, PTGN was diagnosed
in 17.8% of patients with glomerular diseases, compared with
0.0%, 4.4%, 4.9%, and 5.5% of the recipients in renal vascular
diseases, renal interstitial diseases/PN/uropathy, diabetic renal
disease, and hereditary renal diseases group, and in 5.7% of the
patients with diseases of unknown etiologies (Table 2).es
Interstitial/PN/
Uropathy
(N¼45, 5.9%)
Diabetic
(N¼82, 10.7%)
Hereditary
and various
(N¼73, 9.6%)
Unknown
(N¼141, 18.5%)
12 (26.7) 4 (4.9) 13 (17.8) 39 (27.7)
15 (33.3) 23 (28.0) 19 (26.0) 44 (31.2)
18 (40.0) 55 (67.1) 41 (56.2) 58 (41.1)
0 (0) 4 (4.9) 1 (1.4) 9 (6.4)
10 (22.2) 6 (7.3) 7 (9.6) 20 (14.2)
23 (51.1) 40 (48.8) 33 (45.2) 75 (53.2)
12 (26.7) 32 (39.0) 32 (43.8) 37 (26.2)
24 (53.3) 55 (67.1) 45 (61.6) 72 (51.1)
21 (46.7) 42 (52.5) 42 (57.5) 63 (46.3)
27 (60.0) 43 (52.4) 34 (46.6) 82 (58.2)
4 (8.9) 18 (22.0) 18 (24.7) 24 (17.0)
14 (31.1) 21 (25.6) 21 (28.7) 35 (24.8)
41 (91.1) 78 (95.2) 70 (95.9) 60 (42.6)
4 (8.9) 2 (2.4) 3 (4.1) 77 (54.6)
0 (0) 2 (2.4) 0 (0) 4 (2.8)
10 (22.2) 22 (26.8) 29 (39.7) 50 (35.5)
1 (2.2) 82 (100.0) 3 (4.1) 2 (1.4)
20 (44.4) 58 (70.7) 33 (45.2) 89 (63.1)
20 (44.4) 42 (51.2) 27 (37.0) 72 (51.1)
24 (53.4) 38 (46.4) 46 (63.0) 68 (48.2)
1 (2.2) 2 (2.4) 0 (0) 1 (0.7)
5 (11.1) 2 (2.4) 8 (11.0) 15 (10.6)
34 (75.6) 77 (93.9) 56 (76.7) 102 (72.3)
6 (13.3) 3 (3.7) 9 (12.3) 24 (17.1)
0 (0) 0 (0) 0 (0) 0 (0)
20 (44.4) 46 (56.1) 38 (52.1) 53 (37.6)
35.22712.71 52.1079.18 39.84713.43 39.65710.46
37.98712.52 40.44714.77 40.79712.92 38.38712.57
phritis.
Figure 1. Incidence rate of post-transplant glomerulonephritis (PTGN)
compared with acute rejection. The incidence rate of PTGN increased
steadily and consistently over the duration of follow-up, whereas acute
rejection occurred rapidly in the early post-transplant period, and the
slope decreased thereafter.
Table 2. Association between underlying kidney diseases and the incidence of PTGN
Underlying kidney disease N Patients with PTGN
IgAN FSGS MPGN MN Immune-mediated GN
Lupus
nephritis
Incidence
of PTGN (%)n
Glomerular 292 42 4 2 1 2 1 52 (17.8)
Biopsy proven
IgAN 129 19 1 0 0 0 0 20 (15.5)
FSGS 16 4 1 0 0 0 0 5 (31.3)
MPGN 8 0 0 1 0 1 0 2 (25.0)
MN 4 0 0 0 0 0 0 0 (0.0)
Lupus nephritis 14 0 0 0 0 0 1 1 (7.1)
Other GN 24 0 1 1 0 0 0 2 (8.3)
Clinically diagnosed 97 19 1 0 1 1 0 22 (22.7)
Vascular 131 0 0 0 0 0 0 0 (0.0)
Interstitial/PN/Uropathy 45 2 0 0 0 0 0 2 (4.4)
Diabetic 82 3 1 0 0 0 0 4 (4.9)
Hereditary/various 73 1 1 1 1 0 0 4 (5.5)
Unknown 141 6 2 0 0 0 0 8 (5.7)
Total 764 54 8 3 2 2 1 70 (9.2)
n Incidence rate of developing PTGN in each group of underlying renal diseases.
FSGS, focal segmental glomerulosclerosis; GN, glomerulonephritis; IgAN, immunoglobulin A nephropathy; MN, membranous nephropathy; MPGN,
membranoproliferative GN; PN, pyelonephritis; PTGN, post-transplantation glomerulonephritis.
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PTGN increased more rapidly than in other groups (Fig. 3A).
Among all types of PTGN, the most common type was IgAN
(77.1%), followed by FSGS (8.6%) and MPGN (5.7%) (Table 2).
Allograft survival was markedly decreased in patients with
PTGN (Po0.001) (Fig. 2A). When we analyzed graft survival
by the incidence of PTGN and acute rejection, we found that
as PTGN developed, the risk of graft failure increased by 4.02-
folds [95% conﬁdence interval (CI): 1.74–9.29, P¼0.001]. In
case of the occurrence of both acute rejection and PTGN, the
hazard ratio (HR) of graft failure was 7.11 (95% CI: 2.96–17.07,
Po0.001). After adjusting for other risk factors, PTGN was the
strongest risk factor for graft failure (Table 3, Fig. 2B).
In addition, we identiﬁed graft survival by the incidence of
PTGN, acute rejection, and chronic rejection including chronic
allograft nephropathy (CAN). In any combinations of the
development of acute rejection and CAN, as PTGN developed,
the risk of graft failure increased to a considerable extent
(Table 4). However, the number of patients with the occur-
rence of all of them was small, so HR of graft failure seems to
be underestimated.
When analyzing the effects of several types of PTGN on
allograft survival, there was no signiﬁcant difference between
IgAN, FSGS, MPGN, and immune-mediated GN, and this differ-
ence was also veriﬁed using Kaplan–Meier analysis (Supple-
mentary Table 2, Supplementary Fig. 1).Risk factors for the development of PTGN
Of the underlying kidney diseases, glomerular disease was a
signiﬁcant risk factor for PTGN (HR: 3.63, 95% CI: 1.73–7.65,
P¼0.001; Table 5, Fig. 3A). The incidence of PTGN increased
in patients who had kidney transplantation since 2001, espe-
cially after 2006 (HR: 2.52, 95% CI: 1.16–5.46, P¼0.019);
however, after adjusting for other risk factors, this was not
found to be statistically signiﬁcant.
By contrast, there was no difference in PTGN development
according to age, gender, donor type, timing of referral, and pre-
emptive transplantation. HLA mismatch was also not signiﬁ-
cantly associated with the development of PTGN.The use of antimetabolites such as MMF and azathioprine
did not inﬂuence the development of PTGN. The administra-
tion of basiliximab before transplantation and the use of
tacrolimus actually increased the incidence of PTGN, and in
multivariate analysis, these results were found to be statisti-
cally signiﬁcant (HR: 1.89, 95% CI: 1.08–3.32, P¼0.027) (HR:
2.10, 95% CI: 1.25–3.54, P¼0.005) (Table 4, Figs. 3B and 3C).Discussion
The aim of this study was to analyze PTGN incidence, its
relationship with allograft failure, and the risk factors for PTGN
development. PTGN increased over the duration of follow-up,
reaching a cumulative probability of 17.0% after 10 years. The
development of PTGN signiﬁcantly decreased allograft survival.
Among underlying kidney diseases, the highest occurrence of
PTGN was in the glomerular diseases group, with the most
common type being IgAN. Also, we demonstrated that PTGN
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graft loss, irrespective of the type of PTGN, and that PTGN
incidence markedly increased in patients with baseline100A
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Figure 2. Effect of both post-transplant glomerulonephritis (PTGN)
and acute rejection (AR) on graft survival. (A) Association between
PTGN prevalence and graft failure. The development of PTGN was an
obvious risk factor for kidney allograft failure. In patients with PTGN,
graft survival decreased signiﬁcantly (Po0.001). (B) Effects of AR and
PTGN on graft failure. As PTGN developed, the incidence of graft failure
signiﬁcantly increased. Furthermore, the presence of both AR and PTGN
caused kidney allograft failure to increase. *Patients without occur-
rence of both acute rejection and PTGN, yPatients with occurrence of
PTGN, but without acute rejection, zPatients with occurrence of acute
rejection, but without PTGN, yPatients with occurrence of both acute
rejection and PTGN
Table 3. Effects of acute rejection and PTGN on graft failure
N Univariate
HR (95% CI)
Acute rejection–PTGN–y 564 Reference
Acute rejection–PTGNþz 46 3.84 (1.68–8.77)
Acute rejectionþPTGN–y 132 4.79 (2.65–8.65)
Acute rejectionþPTGNþJ 22 6.22 (2.62–14.76)
n Adjusted for the following variables: underlying renal diseases, the era of
recipient and donor, donor type, timing difference of referral, pre-emptive
y Patients without occurrence of both acute rejection and PTGN.
z Patients with occurrence of PTGN, but without acute rejection.
y Patients with occurrence of acute rejection, but without PTGN.
J Patients with occurrence of both acute rejection and PTGN.
HR, hazard ratio; PTGN, post-transplantation glomerulonephritis.glomerular diseases and with the use of tacrolimus and basilix-
imab. We investigated the clinical courses and prognosis of
patients, including PTGN and allograft survival in the unknown
etiology group. In many previous studies, these outcomes were
analyzed only in patients with pathologically conﬁrmed or
presumed glomerular diseases.
The results of our study are consistent with those of an
earlier study, which reported that the incidence of PTGN among
patients who underwent kidney transplantation after 2001 was
signiﬁcantly higher than those who underwent transplantation
before 2001, and that the risk for allograft failure was deﬁnitely
increased in patients with PTGN [12]. Because chronic trans-
plant glomerulopathy conﬁrmed by pathologists was excluded
from the analysis of graft survival, we were able to verify the
effect of only PTGN on allograft failure in this study.
PTGN developed steadily and consistently, and allograft
loss due to PTGN increased throughout the follow-up period,
while the incidence of allograft loss due to acute rejection was
the highest 1 year after transplantation, but rapidly decreased
thereafter [13]. This ﬁnding suggests that the current immu-
nosuppression regimens do not inﬂuence the incidence and
course of PTGN, similar to the ﬁndings reported by Briganti
et al. [12,13]. In addition, our ﬁndings are conﬁrmed by the
presence of pathologically conﬁrmed glomerular diseases in
the native kidney as a critical predictor of PTGN [13]. Also,
this study veriﬁed the poorest graft survival in patients with
both acute rejection and PTGN.
Moreover, the fact that administration of tacrolimus
increased PTGN is conﬁrmed by the results of a previous study
in which recipients treated with tacrolimus instead of CsA had
more frequent proteinuria and an increased risk of graft failure
[14]. As proteinuria is a primary manifestation of GN, patients
with PTGN have more proteinuria, interstitial change, and
glomerular change, and eventually progress to allograft loss [15].
Among underlying glomerular diseases, FSGS recurred in
5 of the 16 patients (31.3%), while the MPGN and IgAN
recurrence rate were 25.0% and 15.5%, respectively. These
results were comparable with usual recurrence rates reported
previously. By contrast, MN did not recur compared with the
expected rate of 10–30%; it is assumed that this difference is
due to demographic differences in the study population of our
centers, and that the recurrence rate will increase with longer
follow-up periods [7].
In addition, our ﬁndings differ from those of Karakayali
et al. in that the recurrence rates were similar among patients
taking either tacrolimus or CsA [16] and from those of Gastonanalysis Multivariate analysisn
P HR (95% CI) P
Reference
0.001 4.02 (1.74–9.29) 0.001
o0.001 5.40 (2.94–9.93) o0.001
o0.001 7.11 (2.96–17.07) o0.001
transplantation, human leukocyte antigen mismatch, age and gender of
transplantation, and administered immunosuppressants.
Table 5. Multiple risk factors for developing PTGN
Univariate analysis Multivariate analysisn
HR (95% CI) P HR (95% CI) P
Underlying kidney disease
Unknown Reference Reference
Glomerular 3.63 (1.73–7.65) 0.001 4.01 (1.82–8.84) 0.001
Vascular 0.00 0.953 0.00 0.953
Interstitial/PN/Uropathy 0.83 (0.18–3.91) 0.815 0.84 (0.17–4.04) 0.826
Diabetic 1.63 (0.49–5.46) 0.428 1.88 (0.54–6.53) 0.320
Hereditary/various 1.27 (0.38–4.23) 0.695 1.23 (0.36–4.22) 0.743
Era
1995–2000 Reference
2001–2005 1.76 (0.94–3.31) 0.080
2006–2010 2.52 (1.16–5.46) 0.019
HLA mismatch
0 Reference
1–3 0.86 (0.43–1.74) 0.680
4–6 1.04 (0.49–2.23) 0.917
Age at transplant (y)
1st percentile Reference
2nd percentile 0.84 (0.46–1.53) 0.566
3rd percentile 0.60 (0.30–1.23) 0.165
4th percentile 0.82 (0.43–1.59) 0.564
Donor age (y)
1st percentile Reference
2nd percentile 0.58 (0.31–1.09) 0.090
3rd percentile 0.62 (0.32–1.21) 0.160
4th percentile 0.62 (0.32–1.20) 0.156
Male gender (recipient) 0.74 (0.46–1.19) 0.211
Male gender (donor) 1.09 (0.67–1.75) 0.734
Donor type
Living related Reference
Living unrelated 1.08 (0.57–2.05) 0.823
Deceased 1.25 (0.69–2.26) 0.468
Referral
Late referral Reference
Early referral 0.84 (0.50–1.41) 0.510
Pre-emptive transplantation 0.59 (0.35–1.02) 0.058
Immunosuppressant
Purine synthesis inhibitors
Not used Reference
Azathioprine 0.49 (0.22–1.09) 0.079
Mycophenolate mofetil 1.27 (0.65–2.47) 0.489
Calcineurin inhibitor
Cyclosporine A Reference Reference
Tacrolimus 2.26 (1.37–3.72) 0.001 2.10 (1.25–3.54) 0.005
Basiliximab 2.05 (1.20–3.52) 0.009 1.89 (1.08–3.32) 0.027
n Adjusted for the following variables: underlying renal diseases, the era of transplantation, HLA mismatch, age and gender of recipient, pre-
emptive transplantation, and administered immunosuppressants.
CI, conﬁdence interval; DM, diabetes mellitus; GN, glomerulonephritis; HLA, human leukocyte antigen; HR, hazard ratio; HTN, hypertension; PTGN,
post-transplant glomerulonephritis.
Table 4. Effects of acute and chronic rejection, and PTGN on graft failure
N Univariate analysis Multivariate analysisn
HR (95% CI) P HR (95% CI) P
Acute rejection–CAN–PTGN– 536 Reference Reference
Acute rejection–CAN–PTGNþ 34 3.90 (1.42–10.69) 0.008 2.71 (0.87–8.47) 0.087
Acute rejection–CANþPTGN– 22 3.92 (1.30–11.79) 0.015 4.05 (1.16–14.20) 0.029
Acute rejection–CANþPTGNþ 12 5.63 (1.63–19.39) 0.006 5.13 (1.34–19.61) 0.017
Acute rejectionþCAN–PTGN– 98 3.85 (1.82–8.16) o0.001 4.66 (2.03–10.68) o0.001
Acute rejectionþCAN–PTGNþ 14 9.68 (3.76–24.92) o0.001 11.20 (3.81–32.90) o0.001
Acute rejectionþCANþPTGN– 38 8.93 (4.27–18.66) o0.001 9.40 (4.09–21.60) o0.001
Acute rejectionþCANþPTGNþ 10 2.28 (0.30–17.21) 0.426 3.62 (0.39–33.34) 0.256
n Adjusted for the following variables: underlying renal diseases, the era of transplantation, human leukocyte antigen mismatch, age and gender of
recipient and donor, donor type, timing difference of referral, pre-emptive transplantation, and administered immunosuppressants.
CAN, chronic allograft nephropathy; HR, hazard ratio; PTGN, post-transplantation glomerulonephritis.
–, No development; þ , Development.
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Figure 3. Incidence of post-transplant glomerulonephritis (PTGN)
according to the inﬂuence of risk factors. (A) Association between
underlying kidney disease and PTGN. In the glomerular diseases group,
the incidence rate of PTGN is more than in other etiology groups
(Po0.001). The signiﬁcant difference between the glomerular diseases
group and the unknown etiology group was speciﬁcally in the devel-
opment of PTGN (Po0.001). In all groups tested, PTGN increased over
the duration of follow-up. (B) Association between PTGN and the use of
calcineurin inhibitors. The use of tacrolimus increased the PTGN
development compared with cyclosporine (P¼0.001). (C) Association
between PTGN and the use of basiliximab. The use of basiliximab
increased the PTGN development compared with no use of basiliximab
(P¼0.005). PN, pyelonephritis.
Kidney Res Clin Pract 31 (2012) 219–226 225et al. in that the recipients treated with tacrolimus had better
kidney function than those on CsA-based treatment [17].
Furthermore, the results of our study differ from another
study that documented an increasing tendency toward PTGN
development in living related kidney transplants with a
higher degree of HLA matching [18,19].
Our study has a different level of signiﬁcance compared
with others, in that we demonstrated a positive correlation
between the use of tacrolimus and basiliximab and PTGN.
Even if better immunosuppression regimens decrease post-
transplant complications, including treatment-resistant rejec-
tion and overall long-term mortality, prolonged graft survivaland rejection-free survival were thought to contribute to the
higher incidence of PTGN [20]. In addition, completeness of
follow-up of the cohorts with the administration of tacroli-
mus and basiliximab might inﬂuence this result.
After adjusting for multiple factors such as increased numbers
of kidney biopsies, advances in medicine, and more accurate
interpretations of pathologic results, our results appear to be
meaningful. It is noteworthy that a cohort of three centers in Asia
became the subject of this study and the duration of follow-up
was long enough to obtain an accurate interpretation of these
results.
Also, even in cases of underlying diabetic renal diseases,
PTGN occurred to a considerable extent accounting for 4.9%. It
suggests that some patients with diabetes mellitus and renal
failure may have underlying glomerular diseases, and there-
fore the patients without typical features and courses of
diabetic renal diseases should have kidney biopsies taken to
evaluate underlying glomerular diseases.
There were several limitations to our study. First, it was
not possible to distinguish de novo glomerular diseases from
recurrent glomerular diseases in a few patients, because
pathologically unproven or only clinically diagnosed glomer-
ular diseases were included in the underlying glomerular
diseases group without clear criteria for classiﬁcation, and
141 (18.5%) patients had diseases with unknown etiologies
despite classifying the underlying kidney diseases into
six groups. Also, some patients were categorized as having
original renal diseases without deﬁnite criteria. In other
words, true incidence and inﬂuence of PTGN is underesti-
mated or overestimated in this group. Thus, we need to design
a follow-up study with an accurate classiﬁcation of de novo
and recurrent GN. Second, biopsies of the allograft appeared
to be performed more often in patients who underwent
transplantation after 2001, regardless of the level of protei-
nuria (Supplementary Table 1). This could have contributed to
an exaggerated effect on the analysis of results. Accordingly,
veriﬁcation of the effects of tacrolimus and basiliximab
should be practiced through well-designed, multicentered,
prospective and large cohort studies in the future.
It is expected that the number of kidney transplants will
increase, and developing effective immunosuppression treat-
ment methods will reduce early and late complications, and
enhance comprehensive outcomes and survival rates after
transplantation. In this light, the importance of PTGN will be
emphasized. We demonstrated that PTGN has a prominent and
considerable inﬂuence on allograft survival like acute rejection,
even in transplant recipients with ESRD of unknown etiology.
We suggest that understanding the risk factors and prognosis
of PTGN should play a signiﬁcant role in the monitoring and
management of renal allograft patients in the future.
In conclusion, PTGN was strongly associated with poor
kidney allograft survival. A critical focus of post-transplant
care should be the management of recurrent or de novo GN.Conﬂict of interest
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